New drug combo targets Hard-to-Treat breast cancer

NCT ID NCT02605486

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This clinical trial is testing whether combining two drugs, palbociclib and bicalutamide, is safe and effective for people with a specific type of metastatic breast cancer that is triple-negative and androgen receptor positive. The study involves women whose cancer has spread and who have not responded to other treatments. The goal is to find the best dose and see if the combination can slow or stop cancer growth.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
palbociclib and bicalutamide
What this could lead to
If successful, this combination could offer a new treatment option for people with a hard-to-treat form of metastatic breast cancer.
What could go wrong
This is an early-phase trial with a small number of participants, so the benefits and risks are not yet fully known. The combination may cause side effects or may not improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANDROGEN RECEPTOR POSITIVE METASTATIC BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Memorial Sloan Kettering Cancer Center

    Basking Ridge, New Jersey, United States

  • Memorial Sloan Kettering Cancer Center @ Suffolk

    Commack, New York, 11725, United States

  • Memorial Sloan Kettering Monmouth

    Middletown, New Jersey, 07748, United States

  • Memorial Sloan Kettering Nassau

    Uniondale, New York, 11553, United States

  • Memorial Sloan Kettering Westchester

    Harrison, New York, 10604, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.